Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PERAMPANEL

All strengths: Limited Use — Reason for Use code 430, 564 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 430, 564 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N03AX) — coverage varies; not interchangeable

  • Lamotrigine (Lamictal): general benefit
  • Topiramate (Topamax Sprinkle): general benefit, Limited Use 321, Not a benefit
  • Brivaracetam (Brivlera): limited Use 548
  • Cenobamate (Xcopri): limited Use 719
  • Lacosamide (Vimpat): limited Use 430
  • Levetiracetam (PDP-Levetiracetam): limited Use 473, Limited Use 640, 705

14 more in the class list below

Fycompa · DIN 02404516 · 2mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Fycompa · DIN 02404516 Manufacturer: Eisai Limited; listing date 2014-02-27 Health Canada: Marketed since 2013-06-19 · brand FYCOMPA · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 2 MG · company Eisai limited · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88927 · Verify on the e-Formulary ↗ (DIN 02404516)

Source record
DIN 02404516: Fycompa Raw flags: sec12=Y, sec3=Y Item: 281200161; group id 437; item number 1090; lccId 00240; manufacturer id EIS Source form: Tab; strength: 2mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $10.3869; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404516 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88927
Interchangeable products
Taro-Perampanel · DIN 02522632 · $5.7128
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02404516
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Perampanel · DIN 02522632 · 2mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Taro-Perampanel · DIN 02522632 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2024-01-31 Health Canada: Marketed since 2023-12-04 · brand TARO-PERAMPANEL · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 2 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Perampanel: Formulary list price $5.7128/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101174 · Verify on the e-Formulary ↗ (DIN 02522632)

Source record
DIN 02522632: Taro-Perampanel Raw flags: sec12=Y, sec3=Y Item: 281200161; group id 437; item number 1090; lccId 00240; manufacturer id TAR Source form: Tab; strength: 2mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $5.7128; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522632 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101174
Interchangeable products
Fycompa · DIN 02404516 · $5.7128
Shortage status: resolved shortage (ended 2025-08-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522632
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Fycompa · DIN 02404524 · 4mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Fycompa · DIN 02404524 Manufacturer: Eisai Limited; listing date 2014-02-27 Health Canada: Marketed since 2013-06-19 · brand FYCOMPA · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 4.0 MG · company Eisai limited · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88929 · Verify on the e-Formulary ↗ (DIN 02404524)

Source record
DIN 02404524: Fycompa Raw flags: sec12=Y, sec3=Y Item: 281200162; group id 437; item number 1091; lccId 00240; manufacturer id EIS Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $10.3869; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404524 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88929
Interchangeable products
Taro-Perampanel · DIN 02522640 · $5.7128
Shortage status: resolved shortage (ended 2024-01-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02404524
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Perampanel · DIN 02522640 · 4mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Taro-Perampanel · DIN 02522640 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2024-01-31 Health Canada: Marketed since 2023-12-04 · brand TARO-PERAMPANEL · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 4 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Perampanel: Formulary list price $5.7128/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101175 · Verify on the e-Formulary ↗ (DIN 02522640)

Source record
DIN 02522640: Taro-Perampanel Raw flags: sec12=Y, sec3=Y Item: 281200162; group id 437; item number 1091; lccId 00240; manufacturer id TAR Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $5.7128; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522640 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101175
Interchangeable products
Fycompa · DIN 02404524 · $5.7128
Shortage status: resolved shortage (ended 2025-11-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522640
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Fycompa · DIN 02404532 · 6mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Fycompa · DIN 02404532 Manufacturer: Eisai Limited; listing date 2014-02-27 Health Canada: Marketed since 2013-06-19 · brand FYCOMPA · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 6.0 MG · company Eisai limited · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88930 · Verify on the e-Formulary ↗ (DIN 02404532)

Source record
DIN 02404532: Fycompa Raw flags: sec12=Y, sec3=Y Item: 281200163; group id 437; item number 1092; lccId 00240; manufacturer id EIS Source form: Tab; strength: 6mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $10.3869; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404532 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88930
Interchangeable products
Taro-Perampanel · DIN 02522659 · $5.7128
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02404532
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Perampanel · DIN 02522659 · 6mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Taro-Perampanel · DIN 02522659 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2024-01-31 Health Canada: Marketed since 2023-12-04 · brand TARO-PERAMPANEL · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 6 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Perampanel: Formulary list price $5.7128/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101176 · Verify on the e-Formulary ↗ (DIN 02522659)

Source record
DIN 02522659: Taro-Perampanel Raw flags: sec12=Y, sec3=Y Item: 281200163; group id 437; item number 1092; lccId 00240; manufacturer id TAR Source form: Tab; strength: 6mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $5.7128; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522659 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101176
Interchangeable products
Fycompa · DIN 02404532 · $5.7128
Shortage status: resolved shortage (ended 2026-06-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522659
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Fycompa · DIN 02404540 · 8mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Fycompa · DIN 02404540 Manufacturer: Eisai Limited; listing date 2014-02-27 Health Canada: Marketed since 2013-06-19 · brand FYCOMPA · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 8.0 MG · company Eisai limited · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88931 · Verify on the e-Formulary ↗ (DIN 02404540)

Source record
DIN 02404540: Fycompa Raw flags: sec12=Y, sec3=Y Item: 281200164; group id 437; item number 1093; lccId 00240; manufacturer id EIS Source form: Tab; strength: 8mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $10.3869; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404540 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88931
Interchangeable products
Taro-Perampanel · DIN 02522667 · $5.7128
Shortage status: resolved shortage (ended 2024-01-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02404540
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Perampanel · DIN 02522667 · 8mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Taro-Perampanel · DIN 02522667 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2024-01-31 Health Canada: Marketed since 2023-12-04 · brand TARO-PERAMPANEL · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 8 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Perampanel: Formulary list price $5.7128/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101177 · Verify on the e-Formulary ↗ (DIN 02522667)

Source record
DIN 02522667: Taro-Perampanel Raw flags: sec12=Y, sec3=Y Item: 281200164; group id 437; item number 1093; lccId 00240; manufacturer id TAR Source form: Tab; strength: 8mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $5.7128; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522667 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101177
Interchangeable products
Fycompa · DIN 02404540 · $5.7128
Shortage status: resolved shortage (ended 2024-09-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522667
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Fycompa · DIN 02404559 · 10mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Fycompa · DIN 02404559 Manufacturer: Eisai Limited; listing date 2014-02-27 Health Canada: Marketed since 2013-06-03 · brand FYCOMPA · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 10.0 MG · company Eisai limited · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88932 · Verify on the e-Formulary ↗ (DIN 02404559)

Source record
DIN 02404559: Fycompa Raw flags: sec12=Y, sec3=Y Item: 281200165; group id 437; item number 1094; lccId 00240; manufacturer id EIS Source form: Tab; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $10.3869; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404559 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88932
Interchangeable products
Taro-Perampanel · DIN 02522675 · $5.7128
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02404559
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Perampanel · DIN 02522675 · 10mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Taro-Perampanel · DIN 02522675 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2024-01-31 Health Canada: Marketed since 2023-12-04 · brand TARO-PERAMPANEL · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 10 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Perampanel: Formulary list price $5.7128/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101178 · Verify on the e-Formulary ↗ (DIN 02522675)

Source record
DIN 02522675: Taro-Perampanel Raw flags: sec12=Y, sec3=Y Item: 281200165; group id 437; item number 1094; lccId 00240; manufacturer id TAR Source form: Tab; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $5.7128; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522675 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101178
Interchangeable products
Fycompa · DIN 02404559 · $5.7128
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522675
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Fycompa · DIN 02404567 · 12mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Fycompa · DIN 02404567 Manufacturer: Eisai Limited; listing date 2014-02-27 Health Canada: Marketed since 2013-05-17 · brand FYCOMPA · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 12.0 MG · company Eisai limited · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88928 · Verify on the e-Formulary ↗ (DIN 02404567)

Source record
DIN 02404567: Fycompa Raw flags: sec12=Y, sec3=Y Item: 281200166; group id 437; item number 1095; lccId 00240; manufacturer id EIS Source form: Tab; strength: 12mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $10.3869; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404567 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88928
Interchangeable products
Taro-Perampanel · DIN 02522683 · $5.7128
Shortage status: resolved shortage (ended 2024-01-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02404567
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Perampanel · DIN 02522683 · 12mg · tablet

Limited Use — Reason for Use code 430, 564 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430, 564 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430, 564
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 564 For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Taro-Perampanel · DIN 02522683 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2024-01-31 Health Canada: Marketed since 2023-12-04 · brand TARO-PERAMPANEL · ATC N03AX22 PERAMPANEL · form Tablet · route Oral · ingredients PERAMPANEL 12 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Perampanel: Formulary list price $5.7128/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.7128 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101179 · Verify on the e-Formulary ↗ (DIN 02522683)

Source record
DIN 02522683: Taro-Perampanel Raw flags: sec12=Y, sec3=Y Item: 281200166; group id 437; item number 1095; lccId 00240; manufacturer id TAR Source form: Tab; strength: 12mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $5.7128; ministry $5.7128 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522683 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101179
Interchangeable products
Fycompa · DIN 02404567 · $5.7128
Shortage status: resolved shortage (ended 2026-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522683
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit)

LACOSAMIDE

· 44 products · Limited Use, codes 430 · strengths: 50mg, 100mg, 150mg, 200mg · Tab

LEVETIRACETAM

· 49 products · Limited Use, codes 640, 705 (3), Limited Use, codes 473 (46) · strengths: 100mg/mL, 250mg, 500mg, 750mg, 1000mg · Oral Sol, Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS FYCOMPA (perampanel) tablets are indicated as: • adjunctive therapy in the management of partial-onset seizures in patients 7 years of age and older FYCOMPA® (Perampanel) Page 3 of 55 who are not satisfactorily controlled with conventional therapy. • adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients 12 years of age and older with epilepsy, who are not satisfactorily controlled with conventional therapy. 1.1 Pediatrics Pediatrics (<7 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of FYCOMPA in children under 7 years of age has not been established; therefore, Health Canada has not authorized an indication for this patient population (see 7.1.3 Pediatrics and 10.3 Pharmacokinetics, Special Populations and Conditions). 1.2 Geriatrics Geriatrics (≥65 years of age): There is limited information on the use of FYCOMPA in patients 65 years of age and older. No dose adjustment based on age is necessary. In general, dose sel… https://pdf.hres.ca/dpd_pm/00073371.PDF PM date: Apr 4, 2013 Source product: FYCOMPA; DIN 02404516; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.